RxDoctor Payments Data

Samuel Ramirez, MD

Family Medicine · McAllen, TXNPI 1538190244

Payments from drug & device makers

$16,407in general payments, 2019–2025

Across 1,082 payments — averaging $15.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Novo Nordisk$2K
  • Amgen$2K
  • AstraZeneca$1K
  • Lilly USA, LLC$784
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$683
  • plus $8K from 52 others

What the payments were for

  • Food & beverage$16,26899%
  • Education$1391%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)156$2,096
Novo Nordisk132$2,035
Amgen(2 entities)114$1,723
AstraZeneca70$1,483
Lilly USA, LLC80$784
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC66$683
Pfizer46$642
Amarin Pharma, Inc.50$638
Boehringer Ingelheim27$551
Antares Pharma, Inc.26$353
Astellas Pharma US Inc17$314
Merck20$310
Dexcom, Inc.16$309
Sanofi-aventis U.S. LLC19$308
Phathom Pharmaceuticals, Inc.9$298
Romark Laboratories, LC20$263
Ironwood Pharmaceuticals, Inc14$250
Kowa Pharmaceuticals America, Inc.16$236
Biohaven Pharmaceutical Holding Company Ltd.14$206
Biohaven Pharmaceuticals, Inc.11$197
Johnson & Johnson13$196
Sumitomo Pharma America, Inc.9$180
Takeda Pharmaceuticals U.S.A., Inc.13$177
Teva Pharmaceuticals USA, Inc.10$151
Abbott7$149
Bayer7$147
Radius Health, Inc.7$142
Otsuka America Pharmaceutical, Inc.6$126
Esperion Therapeutics, Inc.8$121
Novartis7$119
Genentech USA, Inc.6$110
Arbor Pharmaceuticals, Inc.7$98
GSK7$97
Mannkind Corporation7$97
Viatris Specialty LLC1$86
Paratek Pharmaceuticals, Inc.5$79
Exact Sciences4$77
Sanofi Pasteur Inc.4$66
Eisai Inc.4$66
Intuity Medical Inc3$52
Urovant Sciences Inc2$46
Mylan Specialty L.p.3$39
Tris Pharma Inc2$31
Shire North American Group Inc2$28
Corcept Therapeutics1$27
Seqirus USA Inc1$25
Phadia US Inc.1$20
Corium, LLC2$20
Madrigal Pharmaceuticals1$19
Averitas Pharma Inc.1$18
Halozyme Inc1$18
Redhill Biopharma Inc.1$18
Avanir Pharmaceuticals, Inc.1$17
AMAG Pharmaceuticals, Inc.1$16
Melinta Therapeutics, LLC1$15
Aytu Biopharma, Inc.1$14
Philips North America LLC1$13
Biogen1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$16,407 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$76,145
Medicare patients
339
Services billed
2,793

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide115$126,376
FarxigaDapagliflozin Propanediol70$84,710
JardianceEmpagliflozin59$62,268
TrulicityDulaglutide44$52,534
EliquisApixaban38$40,422
JanuviaSitagliptin Phosphate28$30,907
XareltoRivaroxaban29$27,424
Janumet XrSitagliptin Phos/Metformin Hcl16$25,089
ProliaDenosumab15$25,034
MyrbetriqMirabegron23$24,536
RybelsusSemaglutide13$22,968
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog26$22,120
Synjardy XrEmpagliflozin/Metformin Hcl20$20,728
MounjaroTirzepatide18$20,151
EntrestoSacubitril/Valsartan22$18,712

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$2,035$149,344128 claims
Boehringer IngelheimJardiance, Synjardy Xr, Tradjenta$551$100,635100 claims
AstraZenecaFarxiga, Brilinta$1,483$93,58484 claims
Lilly USA, LLCTrulicity, Mounjaro$784$72,68562 claims
MerckJanuvia, Janumet Xr$310$55,99544 claims
PfizerEliquis$642$40,42238 claims
Johnson & JohnsonXarelto$196$27,42429 claims
AmgenProlia$1,723$25,03415 claims
Astellas Pharma US IncMyrbetriq$314$24,53623 claims
NovartisEntresto$119$18,71222 claims
Sumitomo Pharma America, Inc.Gemtesa$180$18,53822 claims
AbbVieLinzess, Synthroid$2,096$16,85460 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →